Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:6367 |
| Name | acral lentiginous melanoma |
| Definition | A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin melanoma acral lentiginous melanoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| NRAS G13X | Tunlametinib | acral lentiginous melanoma | predicted - sensitive | detail... |
| NRAS G12D | Tovorafenib | acral lentiginous melanoma | predicted - sensitive | detail... |
| NRAS Q61R | Trametinib | acral lentiginous melanoma | sensitive | detail... |
| KIT L576P | Nilotinib | acral lentiginous melanoma | predicted - sensitive | detail... |
| KIT V559A | Nilotinib | acral lentiginous melanoma | predicted - sensitive | detail... |
| KIT exon 11 del | Nilotinib | acral lentiginous melanoma | predicted - sensitive | detail... |
| KIT I817L | Nilotinib | acral lentiginous melanoma | predicted - sensitive | detail... |
| KIT mutant | Nilotinib | acral lentiginous melanoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Active, not recruiting | AUS | 0 |
| NCT02731729 | Phase II | Ipilimumab Nivolumab | Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | Completed | USA | 0 |
| NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Completed | CAN | 0 |
| NCT02978443 | Phase II | Ipilimumab + Nivolumab | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | Terminated | USA | 0 |
| NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | SWE | NOR | AUS | 0 |
| NCT03817125 | Phase I | Nivolumab + SER-401 Vancomycin Nivolumab | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) | Completed | USA | 0 |
| NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
| NCT04139902 | Phase II | Cobolimab + Dostarlimab-gxly Dostarlimab-gxly | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Active, not recruiting | USA | 0 |
| NCT04244552 | Phase I | ATRC-101 | First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Terminated | USA | 0 |
| NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
| NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
| NCT05061134 | Phase II | Ceralasertib + Durvalumab Ceralasertib | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
| NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | IRL | ESP | CAN | AUS | 2 |
| NCT05098210 | Phase I | NeoVax + Nivolumab + Poly ICLC | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | Recruiting | USA | 0 |
| NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Active, not recruiting | USA | 0 |
| NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 3 |
| NCT06346067 | Phase III | LXH 254 + Trametinib Trametinib Dacarbazine Temozolomide | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | CZE | CAN | AUS | 0 |
| NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06651151 | Phase II | LTX-315 + Pembrolizumab | NeoLIPA: Neoadjuvant LTX-315 in Combination With Pembrolizumab in Resectable Stage III/IV Melanoma (NeoLIPA) | Recruiting | NOR | 0 |
| NCT06743126 | Phase III | Pembrolizumab Temozolomide Carboplatin + Paclitaxel Lifileucel Dacarbazine Nivolumab Paclitaxel Nivolumab and relatlimab-rmbw Nab-paclitaxel Ipilimumab IMA-203 | SUPRAME-ACTengine IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (SUPRAME) | Recruiting | USA | DEU | 0 |
| NCT06794775 | Phase III | Ipilimumab + Nivolumab Nivolumab | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma (SWE-NEO) | Recruiting | SWE | 0 |
| NCT06961357 | Phase Ib/II | Interleukin-12 CD40L-augmented TILs Cyclophosphamide + Fludarabine | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Recruiting | USA | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | GBR | AUS | 0 |
| NCT07155317 | Phase II | Ipilimumab + Nivolumab | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | Recruiting | USA | 0 |